Form 4: Crinetics Pharmaceuticals Executive Stephen F. Betz Reports Acquisition of Stock and Options

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, reports the acquisition of 23,000 shares of common stock and options to purchase 87,000 shares.

Summary

• On March 4, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, acquired 23,000 shares of common stock.
• These shares were received as restricted stock units, vesting 25% annually starting March 15, 2025.
• Betz also acquired options to purchase 87,000 shares of common stock at an exercise price of $43.51.
• These options vest in 48 equal monthly installments beginning March 4, 2024.
• Following these transactions, Betz beneficially owns 96,298 shares of Crinetics Pharmaceuticals.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a key executive is generally a positive sign, but it's a routine transaction and doesn't provide strong evidence for a significant shift in the company's outlook.

Positives

• The acquisition of stock and options by a key executive could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The reported transactions may have a minor positive impact on shareholder sentiment.

Key Dates